OR WAIT null SECS
September 20, 2022
AREDS2 formula doesn’t contain beta carotene, reducing the risk of lung cancer.
September 14, 2022
With the launch of dark adaptation, Heru is now the only platform on the AMD market to include contrast sensitivity and dark adaptation exams.
August 27, 2022
Ashley Tucker, OD, FAAO, FSLS, Dipl ABO, shares highlights from her discussion titled, "Myopia management: past, present, and future," presented during this year's 115th annual SCOPA meeting.
August 26, 2022
Leo P. Semes, OD, FAAO, highlights his presentation on "Artificial intelligence and telemedicine," presented during the 115th annual SCOPA meeting.
Leo P. Semes, OD, FAAO, discusses his presentation on, "A new look at AMD," during the South Carolina Optometric Physicians Association's annual meeting.
August 24, 2022
Latest data from phase 3 studies finds increased effects over time with intravitreal pegcetacoplan for geographic atrophy secondary to age-related macular degeneration.
August 03, 2022
Ranibizumab-eqrn will offer greater treatment access and choice for patients, payors, and providers in the US.
August 01, 2022
Korean investigators have found intermittent fasting may actually lead to a lower risk of developing AMD in the elderly population.
July 19, 2022
If approved, pegcetacoplan—an investigational, targeted C3 therapy—will be the first-ever treatment for GA.
July 15, 2022
Advancements enable better diagnosis, treatment of patients.
Black EyeCare Perspective to host third annual IMPACT HBCU event
Online visual acuity test gains FDA clearance
Debunking common ortho-k myths
Recent study evaluates medications associated with AAC glaucoma risk
